EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroinflammatory Mechanisms and Vocalization Biomarkers in the Pink1-/- Preclinical Model of Parkinson's Disease

Sarah A Lechner, Cynthia A Kelm-Nelson

Medical Research Archives · 24.10.2025 · 13 (10)

DOI: 10.18103/mra.v13i10.6972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 24.10.2025. Verfasst von Sarah A Lechner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Endocrine Surgery, University of Wisconsin, Madison, Wisconsin, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease is a progressive neurodegenerative disorder with an unclear etiology and a long preclinical phase. The multitude of challenges of studying this in humans highlight the need for robust preclinical animal models that accurately reflect the disease's preclinical progression. While traditional neurotoxin models fail to capture the slow, genetic nature of PD, genetic models, such as the phosphatase and tensin homolog-induced putative kinase 1 (Pink1-/-) knockout rat, offer a preclinical, translational approach. This review synthesizes the current understanding of the Pink1-/- rat model, focusing on two key aspects: neuroinflammation and vocalization deficits. The Pink1-/- rat presents early non-motor symptoms, including vocalization deficits, which can serve as a non-invasive, objective, and longitudinal biomarker of disease progression. This review further proposes a direct link between the model's neuroinflammatory profile, characterized by chronic glial activation and the upregulation of inflammatory pathways, and the observed vocal dysfunctions. By bridging these two critical areas, neuroinflammation as a pathological mechanism and vocalizations as a functional readout, this review provides a framework for future investigations into the diagnosis and treatment of Parkinson’s disease and suggests that targeting specific inflammatory pathways could be a viable therapeutic strategy.

Schlagwörter

Stichwörter der Autor:innen

Parkinson diseasebiomarkerneuroinflammationratultrasonic vocalization

Autor:innen und Institutionen

  • Department of Surgery, Division of Endocrine Surgery, University of Wisconsin, Madison, Wisconsin, USA.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Lechner, S. A., & Kelm-Nelson, C. A. (2025). Neuroinflammatory Mechanisms and Vocalization Biomarkers in the Pink1-/- Preclinical Model of Parkinson's Disease. Medical Research Archives, 13(10). https://doi.org/10.18103/mra.v13i10.6972

Vancouver

Lechner SA, Kelm-Nelson CA. Neuroinflammatory Mechanisms and Vocalization Biomarkers in the Pink1-/- Preclinical Model of Parkinson's Disease. Medical Research Archives. 2025;13(10). doi:10.18103/mra.v13i10.6972

BibTeX
@article{Lechner2025,
  author = {Lechner, Sarah A and Kelm-Nelson, Cynthia A},
  title = {Neuroinflammatory Mechanisms and Vocalization Biomarkers in the Pink1-/- Preclinical Model of Parkinson's Disease},
  journal = {Medical Research Archives},
  year = {2025},
  volume = {13},
  number = {10},
  doi = {10.18103/mra.v13i10.6972}
}
Kostenlos starten →